human stem cell derived neurons
< Back to Clinical Trial List

Impact of Cannabis and Synthetic Cannabinoid Use on Quality of Life of Patients with Central Nervous System Tumors

Summary

Studies have raised the question regarding the risks, therapeutic benefits and quality of life benefits, of various cancers when treated with Cannabis. Delta(9)-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) have been shown to inhibit tumor growth in a number of animal models of cancer, including brain tumor; this is in addition to their reported palliative effects on cancer-associated symptoms, including antiemetic effect, appetite stimulation, pain management, mood/anxiety regulation, sleep aide, which inspire approximately 40% of our patients to use such products. Despite this data there are few clinical studies examining whether CBD+THC is safe in patients with brain tumors let alone positively influences survival based or quality of life-based endpoints.

This single-site, prospective observational study will collect data to better understand the patient population and their behavior around cannabis, as well as clinical outcomes that might be linked to the consumption of cannabis. Specifically, the study will assess the impact of cannabis and synthetic cannabinoid use on the quality of life of patients with primary central nervous system (CNS) tumor(s).

Prospective participants do not need to be cannabis users to participate in the study, nor will cannabis be provided as treatment. As an observational study, participants will be asked to complete online questionnaires about their cannabis use (or non-use), along with other quality of life measures. 

 

Inclusion Criteria
  1. Males or females 18 years of age or older
  2. Ability to understand and read English.
  3. Confirmed diagnosis of primary brain or spine tumor
  4. Willing and able to sign an informed consent form
  5. Patients must be willing and able to complete the questionnaires
  6. Any number of recurrences are acceptable.
  7. Patients with Karnofsky Performance Status (KPS) of >60.
  8. Patients must have access to internet-enabled device at the time of the study visit.
Exclusion Criteria
  1. Patients with spread of tumor outside the CNS
  2. Patients with cognitive deficits that prevent them from completing the questionnaires (previously determined by the clinical staff and/or PI).
  3. Patients in hospice care who are unable to answer the questionnaires.
  4. Patients with metastasis or whose primary tumor is located outside of the CNS.
Investigator(s)

Stay Informed